Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
| Previous close | 1.3000 |
| Open | 1.3100 |
| Bid | 1.3100 x 43500 |
| Ask | 1.3200 x 39400 |
| Day's range | 1.2800 - 1.3400 |
| 52-week range | 1.1200 - 2.5450 |
| Volume | |
| Avg. volume | 18,738,180 |
| Market cap | 2.818B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4100 |
| Earnings date | 01 Mar 2024 - 05 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.38 |
PR NewswireSynplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan
Synplogen Co., a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding ("MOU"). Together, Synplogen and Ginkgo intend to accelerate the global development of DNA manufacturing
IPO-Edge.comFreight Farms Emerges as Global AgTech Leader with Small-Scale Solutions
Freight Farms merging with blank-check company Agrinam Acquisition Corp. (TSX: AGRI.U) AgTech startup provides hydroponic farming solutions, with over 600 farms in operation across 40 countries Has largest network of […]
- PR Newswire
Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins
Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive capabilities in strain engineering, optimization and performance, to develop and commercialize a next generation of functional alternative protein.
